PharmaCyte BiotechPMCB.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, PharmaCyte Biotech (PMCB.O) trades at a negative P/E (-0.18x, due to a recent net loss), P/B of 0.12x, P/S of N/A, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 2nd percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/S historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data).
Cross-sectional valuation: its P/B ranks at the 2nd percentile within its industry and the 2nd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 685.30%, ranking at the 97th percentile over the trailing 20Y window.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. PharmaCyte Biotech operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: PMCB · PMCB
Want the full picture on whether PharmaCyte Biotech (PMCB.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -0.18 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 0.12 | ||||||
| P/S (TTM) | N/A | — | — | — | — | — | — |
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 685.30% |